SG11202106878XA - Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies - Google Patents

Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Info

Publication number
SG11202106878XA
SG11202106878XA SG11202106878XA SG11202106878XA SG11202106878XA SG 11202106878X A SG11202106878X A SG 11202106878XA SG 11202106878X A SG11202106878X A SG 11202106878XA SG 11202106878X A SG11202106878X A SG 11202106878XA SG 11202106878X A SG11202106878X A SG 11202106878XA
Authority
SG
Singapore
Prior art keywords
cgrp
antibodies
treatment
medication overuse
overuse headache
Prior art date
Application number
SG11202106878XA
Other languages
English (en)
Inventor
Roger Cady
Jeffrey Smith
Joseph Hirman
Barbara Schaeffler
Lahar Mehta
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SG11202106878XA publication Critical patent/SG11202106878XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202106878XA 2019-01-08 2020-01-08 Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies SG11202106878XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789828P 2019-01-08 2019-01-08
US201962840967P 2019-04-30 2019-04-30
US201962841585P 2019-05-01 2019-05-01
US201962872983P 2019-07-11 2019-07-11
PCT/US2020/012790 WO2020146535A1 (en) 2019-01-08 2020-01-08 Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Publications (1)

Publication Number Publication Date
SG11202106878XA true SG11202106878XA (en) 2021-07-29

Family

ID=71404208

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106878XA SG11202106878XA (en) 2019-01-08 2020-01-08 Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Country Status (24)

Country Link
US (2) US20200216525A1 (https=)
EP (1) EP3908607A4 (https=)
JP (2) JP2022516957A (https=)
KR (1) KR20210114002A (https=)
CN (2) CN119303074A (https=)
AU (1) AU2020207299A1 (https=)
BR (1) BR112020018044A2 (https=)
CA (1) CA3123292A1 (https=)
CL (1) CL2021001813A1 (https=)
CO (1) CO2021008665A2 (https=)
DO (1) DOP2021000145A (https=)
EC (1) ECSP21052193A (https=)
GE (2) GEAP202515689A (https=)
IL (1) IL284677A (https=)
JO (1) JOP20210166A1 (https=)
MA (1) MA54709A (https=)
MX (1) MX2021008268A (https=)
NI (1) NI202100063A (https=)
PE (1) PE20211708A1 (https=)
PH (1) PH12021551494A1 (https=)
SG (1) SG11202106878XA (https=)
TW (1) TW202030205A (https=)
UA (1) UA129265C2 (https=)
WO (1) WO2020146535A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
EP4570913A1 (en) * 2022-08-11 2025-06-18 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
CN118476508A (zh) * 2024-06-27 2024-08-13 中国人民解放军总医院第一医学中心 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
CN103585449B (zh) * 2013-10-23 2016-06-22 高丽丽 用于治疗偏头痛的中药组合物
US10899834B2 (en) * 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
CN119303074A (zh) 2025-01-14
AU2020207299A1 (en) 2021-08-26
PE20211708A1 (es) 2021-09-01
MA54709A (fr) 2022-04-13
UA129265C2 (uk) 2025-03-05
NI202100063A (es) 2021-12-01
CA3123292A1 (en) 2020-07-16
GEP20257804B (en) 2025-10-10
US20240343784A1 (en) 2024-10-17
GEAP202515689A (en) 2025-04-25
CL2021001813A1 (es) 2021-12-24
JP2022516957A (ja) 2022-03-03
PH12021551494A1 (en) 2023-05-08
WO2020146535A1 (en) 2020-07-16
DOP2021000145A (es) 2021-10-31
JP2025032102A (ja) 2025-03-11
CN113272324A (zh) 2021-08-17
EP3908607A4 (en) 2022-10-05
CO2021008665A2 (es) 2021-07-19
IL284677A (en) 2021-08-31
MX2021008268A (es) 2021-08-05
BR112020018044A2 (pt) 2021-08-10
JOP20210166A1 (ar) 2023-01-30
US20200216525A1 (en) 2020-07-09
KR20210114002A (ko) 2021-09-17
ECSP21052193A (es) 2021-08-31
EP3908607A1 (en) 2021-11-17
TW202030205A (zh) 2020-08-16

Similar Documents

Publication Publication Date Title
SG11202106878XA (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
SG11202106766SA (en) Acute treatment and rapid treatment of headache using anti-cgrp antibodies
ZA202004735B (en) Anti-pd-1 antibodies and methods of treatment
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
IL273841A (en) Antibodies directed against cd137 and methods of their use
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
IL280225A (en) New antibodies against CD47 and methods of using them
EP3244926A4 (en) Treatment of cancer with anti-lap monoclonal antibodies
IL268160A (en) Anti-TNF antibodies, preparations and methods for the treatment of active ankylosing spondylitis
ES3064823T3 (en) Anti-ly6g6d antibodies and methods of use
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL325567A (en) Methods of treatment using anti-il-17a/f antibodies
IL287282A (en) Anti-mertk antibodies and methods of using them
SG11202104222TA (en) Method of treatment of biological surfaces
IL290741A (en) Antibodies against cd-96 and methods of using them
IL289656A (en) Anti-tigit antibodies and their application
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
ZA201805051B (en) Egfl6 specific monoclonal antibodies and methods of their use
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
IL281767A (en) CD137-directed antibodies and methods of using them
EP3962522A4 (en) Treatment of headache using anti-cgrp antibodies
SG11202112352TA (en) Expression of antigen-binding proteins in the nervous system
HK40063199A (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
ZA202201160B (en) Anti-grp78 antibodies and method of use thereof